The oral bioavailability of some drugs is markedly lower in cynomolgus monkeys than in humans. One of the reasons for the low bioavailability in cynomolgus monkeys may be the higher metabolic activity of intestinal CYP3A; however, the species differences in intestinal metabolic activities of other CYP isoforms between cynomolgus monkeys and humans are not well known. In the present study, we investigated the intrinsic clearance (CL int ) values in pooled intestinal microsomes from cynomolgus monkeys and humans using 25 substrates of human CYP1A2, CYP2J2, CYP2C, and CYP2D6. As in humans, intestinal CL int values of human CYP1A2 and CYP2D6 substrates in cynomolgus monkeys were low. On the other hand, intestinal CL int values of human CYP2J2 and CYP2C substrates in cynomolgus monkeys were greatly higher than those in humans. Using immunoinhibitory antibodies and chemical inhibitors, we showed that the higher intestinal CL int values of the human CYP2J2 and CYP2C substrates in cynomolgus monkeys might be caused by monkey CYP4F and CYP2C subfamily members, respectively. In conclusion, there is a possibility that the greatly higher metabolic activity of CYP2C and CYP4F in cynomolgus monkey intestine is one of the causes of the species difference of intestinal first-pass metabolism between cynomolgus monkeys and humans.
Introduction
Cynomolgus monkeys are sometimes used in preclinical studies as nonhuman primates because of their genetic similarity to humans. However, the oral bioavailability of some drugs is markedly lower in cynomolgus monkeys than in humans. 1¥ This is often speculated to be caused by extensive first-pass metabolism in the cynomolgus monkey intestine.
2®4¥
Cytochrome P450 ¤CYP¥ is the most important drugmetabolizing enzyme family contributing to the metabolism of the majority of drugs in humans and is involved in firstpass metabolism in intestine.
5,6¥ It has been reported that CYP2C9, CYP2C19, CYP2D6, CYP2J2, CYP3A, and CYP4F proteins are expressed in human intestine.
7,8¥ In cynomolgus monkey intestine, Uno et al. reported that CYP2J2, CYP3A, and CYP4F mRNAs are highly expressed and CYP2C and CYP2D mRNAs are slightly expressed.
9®11¥
In both cynomolgus monkeys and humans, the same CYP subfamilies, which exhibit a high degree of homology, are expressed in intestine. Although all members of the P450 superfamily possess highly conserved regions of amino acid residues, even small changes in the amino acid sequences can result in profound differences in substrate specificity and catalytic activity.
12,13¥ Thus, we speculated that species differences in drug bioavailability between cynomolgus monkeys and humans are caused by species differences in metabolic activities of CYP.
It is now well known that many drugs metabolized by CYP3A undergo first-pass metabolism in the intestine of both cynomolgus monkeys and humans. We previously reported that the intestinal metabolic activity in cynomolgus monkeys toward human CYP3A substrates was higher than that in humans. 14¥ Therefore, one of the reasons for low bioavailability in cynomolgus monkeys may be the higher metabolic activity of intestinal CYP3A. However, the species differences in intestinal metabolic activities of other P450 isoforms between cynomolgus monkeys and humans are not well known.
The purpose of this study was to investigate species differences between intestinal metabolic activity in cyno-molgus monkeys and humans. In the present study, we investigated the intrinsic clearance ¤CL int ¥ values in pooled intestinal microsomes from cynomolgus monkeys and humans using 25 substrates of human CYP1A2, CYP2J2, CYP2C, and CYP2D6. Furthermore, concerning the compounds undergoing metabolic activities in cynomolgus monkey intestine, we estimated the major members of the cynomolgus monkey CYP subfamily involved in the metabolic activities.
Materials and Methods
Chemicals: Lidocaine, tacrine hydrochloride, tizanidine hydrochloride, triamterene, amodiaquine dihydrochloride dehydrate, tolbutamide, diclofenac sodium salt, alprenolol hydrochloride, ¤+¥-bufuralol hydrochloride, desipramine hydrochloride, fluoxetine hydrochloride, fluvoxamine maleate, imipramine hydrochloride, lansoprazole, paroxetine maleate, ¤+¥-propranolol hydrochloride, ¤R¥-tomoxetine hydrochloride, astemizole, flecainide acetate, nicardipine hydrochloride, nimodipine, 17-octadecynoic acid ¤17-ODYA¥, and terfenadine were purchased from SigmaAldrich Co. ¤St. Louis, MO, USA¥. Phenacetin, theophylline, paclitaxel, phenytoin, S-¤%¥-warfarin, and omeprazole were purchased from Wako Pure Chemical Industries Ltd. ¤Osaka, Japan¥. Ç-NADPH was purchased from Oriental Yeast Co., Ltd. ¤Tokyo, Japan¥. All other reagents and solvents were of analytical grade and were commercially available.
Microsomes and immunoinhibitory antibodies: Pooled intestinal and liver microsomes from 4-to 8-year-old male cynomolgus monkeys ¤MIM and MLM¥ and 5-to 70-year-old humans ¤HIM and HLM¥ were purchased from Xenotech, LLC ¤Lenexa, KS¥. Polyclonal antibodies ¤anti-sera¥ against human CYP2C8, human CYP2C9, human CYP2C19, human CYP3A4, and rat CYP2J raised in rabbits were purchased from Nosan Corporation ¤Kanagawa, Japan¥. Anti-rat CYP2J has an inhibitory effect on human CYP2J2.
15¥
Metabolic stabilities in liver and intestinal microsomes: We incubated the compounds at 37ôC in 100 µL of a reaction mixture consisting of 50 mM potassium phosphate buffer ¤pH 7.4¥ and 3 mM NADPH with microsomes from cynomolgus monkeys or humans. The linearity of metabolic activities for microsomal concentrations ¤0.001®0.2 mg protein/mL¥, substrate concentrations ¤10® 200 nM¥, and incubation times ¤15 or 30 min¥ were confirmed, and the optimal reaction conditions were set for each compound. The final concentration of acetonitrile in the incubation mixture was 0.5% ¤v/v¥. After preincubation at 37ôC for 5 min, the reactions were initiated by the addition of the NADPH solution and stopped by addition of 200 µL of ice-cold methanol. Control samples were incubated using the same method in the absence of NADPH; NADPH was added after the addition of ice-cold methanol.
The reaction mixtures were spiked with 200 µL of methanol containing the internal standard, 200 nM flecainide. The mixtures were centrifuged at 3400 ' g for 10 min to remove precipitated protein. The supernatants were then filtrated using 0.45-µm 96-well filter plates ¤Varian Inc., Palo Alto, CA¥. The filtrates were diluted 2-fold using distilled water and transferred to 96-well plates, and a 10-µL portion was injected into a high-performance liquid chromatography with tandem mass spectrometry ¤HPLC/ MS/MS¥ system.
Identification of metabolic enzymes in cynomolgus monkey intestine using immunoinhibitory antibodies: Amodiaquine and lansoprazole ¤200 nM, final concentration¥ were incubated at 37ôC for 15 min in 100 µL of a reaction mixture consisting of 50 mM potassium phosphate buffer ¤pH 7.4¥; MIM ¤1 mg/mL amodiaquine; 0.5 mg/mL lansoprazole¥; immunoinhibitory antibodies against CYP2C8, CYP2C9, CYP2C19, or CYP3A4 ¤0, 2, 5, or 10 µL¥ diluted with preimmune serum ¤10, 8, 5, or 0 µL¥; and 3 mM NADPH to assess the change in percentage of substrate consumed. Preincubation of the microsomes with antiserum or preimmune serum was performed at room temperature for 15 min prior to starting the reaction. Subsequently, the assay was performed as described under Metabolic stabilities in liver and intestinal microsomes.
Astemizole, terfenadine, nicardipine, or nimodipine ¤200 nM, final concentration¥ was incubated at 37ôC for 15 min in 100 µL of a reaction mixture consisting of 50 mM potassium phosphate buffer ¤pH 7.4¥, MIM ¤0.5 mg/mL nimodipine, 0.25 mg/mL nicardipine, astemizole, and terfenadine¥, immunoinhibitory antibodies against CYP3A4 or CYP2J2 ¤0, 2, 5, or 10 µL¥ diluted with preimmune serum ¤10, 8, 5, or 0 µL¥, and 3 mM NADPH to assess the change in percentage of substrate consumed. Preincubation of the microsomes with antiserum or preimmune serum was performed at room temperature for 15 min prior to starting the reaction. Subsequently, the assay was performed as described under Metabolic stabilities in liver and intestinal microsomes.
Identification of metabolic enzymes in cynomolgus monkey intestine using chemical inhibitors: Astemizole and terfenadine ¤200 nM, final concentration¥ were incubated at 37ôC for 15 min in 100 µL of a reaction mixture consisting of 50 mM phosphate buffer ¤pH 7.4¥, MIM ¤0.01 mg/mL, final¥, 17-ODYA ¤a mechanism-based inhibitor for the CYP4 family; 0, 10, 50, or 100 µM, final concentration¥, and 3 mM NADPH to assess the change in percentage of substrate consumed.
16®18¥ 17-ODYA was preincubated with MIM and NADPH at 37ôC for 30 min in the absence of astemizole and terfenadine prior to starting the reaction. Subsequently, the assay was carried out as described under Metabolic stabilities in liver and intestinal microsomes.
The fraction unbound in microsomal incubations: The fraction unbound in microsomal incubations ¤fu mic ¥ for all compounds was determined using a highthroughput dialysis method. Dialysis membranes had a 10-kDa molecular mass cutoff and were purchased from Harvard Apparatus Inc. ¤Holliston, MA, USA¥. Compounds ¤1 µM, final concentration¥ with 0.2 mg protein/mL HLM or HIM in 50 mM phosphate buffer ¤pH 7.4¥ were added to the acceptor chamber, and 50 mM phosphate buffer ¤pH 7.4¥ was added to the donor chamber. The dialysis plate was placed in an incubator at 37ôC for 22 h on a plate rotator. After equilibrium was achieved, 30-µL samples from the acceptor chamber were mixed with 30 µL of 50 mM phosphate buffer ¤pH 7.4¥, and 30-µL samples from the donor chamber were mixed with 30 µL of 0.2 mg protein/mL microsomes in 50 mM phosphate buffer ¤pH 7.4¥. These buffered samples were each mixed with 240 µL methanol containing the internal standard, 200 nM flecainide. The mixtures were centrifuged at 3400 ' g for 10 min to remove precipitated protein. The supernatants were then filtrated using 0.45-µm 96-well filter plates ¤Varian, Inc., Palo Alto, CA, USA¥. The filtrates were diluted 2-fold using distilled water and transferred to 96-well plates, and a 10-µL portion was injected into the HPLC/MS/MS system.
Analytical procedure: The concentrations of the compounds in the samples were measured using an HPLC/ MS/MS method consisting of a TSQ 7000 triple-quadrupole mass spectrometer ¤Thermo Fisher Scientific Inc., Waltham, MA, USA¥ with a Shimadzu 10A series HPLC system ¤Shimadzu Corporation, Kyoto, Japan¥ or a TSQ Quantum Ultra mass spectrometer ¤Thermo Fisher Scientific Inc¥ with a Shimadzu 20A series HPLC system ¤Shimadzu Corporation, Kyoto, Japan¥. Chromatography was performed using an Inertsil ODS-3 column ¤3-µm particle size, 2.1 ' 50 mm, GL Science, Tokyo, Japan¥ warmed to 40ôC. The mobile phase consisted of 0.1% formic acid ¤A¥ and methanol ¤B¥. The flow rate was 0.2 mL/min and the gradient conditions for elution were as follows: gradient ªmin, B%« © ª0, 10«-ª1, 90«-ª3, 90«-ª3.1, 10«-ª6, 10«. Mass spectrometry detections were performed by positive ionization electrospray. A selective reaction monitoring mode was used as follows to monitor precursor ions G product ions: lidocaine ¤235.2 G 86.0¥, phenacetin ¤180.1 G 138.1¥, tacrine ¤198.9 G 170. Data analysis: The peak area ratios of test compounds to the internal standard were used for the calculation in all experiments. The mean value of duplicate determinations was plotted versus the incubation time on a semi-logarithmic scale, and the slope was determined by linear-regression analysis as the elimination rate constant ªk el ¤min %1 ¥«. The CL int values were calculated using the following equation:
When the remaining ratio of the compounds incubated for 30 min with 0.2 mg protein/mL was h90%, CL int values were not calculated ¤CL int g 0.018 mL/min/mg protein¥ and were plotted as 0.01 in Figure 1 .
The fu mic value in each microsomal concentration was calculated by fitting fu mic in a microsomal concentration of 0.2 mg protein/mL ¤fu mic,0.2 mg protein/mL ¥ to the Langmuir equation. It was assumed that fu mic in intestinal and liver microsomes of animals were respectively equivalent to that of humans. The fu mic,0.2 mg/mL value in the incubation mixture of HLM or HIM was calculated using the following equation, and subsequently the mean of duplicate determinations were calculated. fu mic,0:2 mg=mL ¼ peak area in buffer sample/peak area internal standard peak area in microsomal sample/peak area internal standard
Results and Discussion
The purpose of this study was to investigate the species differences between the intestinal metabolic activity in cynomolgus monkeys and humans. In the present study, we investigated the intrinsic clearance ¤CL int ¥ values in pooled intestinal microsomes from cynomolgus monkeys and humans using 25 substrates of human CYP1A2, CYP2J2, CYP2C, and CYP2D6. Furthermore, concerning the compounds targeted by metabolic activities in cynomolgus monkey intestine, we estimated the major members of the cynomolgus monkey CYP subfamily involved in the metabolic activities.
Intestinal CL int values of human CYP2C substrates in cynomolgus monkeys were much higher than those in humans ¤Table 1 and Fig. 1A¥ . Amodiaquine ¤metabolized by human CYP2C8¥ and lansoprazole ¤metabolized by human CYP2C19¥ were metabolized in the cynomolgus monkey intestine and the metabolic activities were inhibited by all anti-human CYP2C8, CYP2C9, and CYP2C19 antibodies but not by anti-human CYP3A antibodies ¤Table 1 and Fig. 2¥ . Because cynomolgus monkey CYPs have a high homology to human CYPs, 19¥ polyclonal antibodies against the human CYP subfamily may cross-react with a similar monkey CYP subfamily. As a result, the CYP2C subfamily might be involved in high cynomolgus monkey intestinal metabolic activity, although the isoforms involved are unclear. In addition, there is a possibility that similar CYP2C isoforms are involved in the metabolic activities of the intestine and the liver, because the monkey CL int values in intestine showed good correlation with those in liver ¤Fig. 1B¥.
Among the compounds we used in this study, astemizole and terfenadine are reported to be substrates of human CYP2J2 in addition to CYP3A4. 20, 21¥ Compared to the other CYP3A substrates, intestinal CL int values of astemizole and terfenadine in cynomolgus monkeys were considerably higher than those in humans ¤Fig. 1A¥. Uno et al. reported that CYP3A, CYP2J, and CYP4F mRNAs are expressed in cynomolgus monkey intestine.
9,10¥ The metabolic activities toward nicardipine and nimodipine, which were used as control CYP3A substrates, in cynomolgus monkey intestines were mainly inhibited by immunoinhibitory antibodies , 14) and CYP3A+CYP2J2 substrates, respectively. When the remaining ratio after incubation for 30 min with 0.2 mg microsomal protein/mL was >90%, CL int values were not calculated (CL int < 0.018 mL/min/mg protein) and were plotted as 0.01. against CYP3A, by 100% and >90%, respectively ¤Figs. 3A and 3B¥. On the other hand, the metabolic activities toward astemizole and terfenadine in cynomolgus monkey intestines were not inhibited by immunoinhibitory antibodies against CYP3A and CYP2J ¤Figs. 3C and 3D¥. Furthermore, the metabolic activities toward astemizole and terfenadine in cynomolgus monkey intestines were largely inhibited ¤by about 40% and 60%, respectively¥ by 17-ODYA, which is a mechanism-based inhibitor for the CYP4 family ¤Figs. 4A and 4B¥. The investigation using chemical inhibitors and immunoinhibitory antibodies suggested that CYP4F might be mainly involved in cynomolgus monkey intestinal metabolism of astemizole and terfenadine. Furthermore, intestinal CYP4F in cynomolgus monkeys plays an important role in the first-pass metabolism of ebastine, which is metabolized by human CYP2J2. 15¥ These results showed that human CYP2J2 substrates were considerably metabolized by CYP4F in cynomolgus monkey intestine.
B A
Intestinal CL int values of human CYP1A2 and CYP2D6 substrates both in cynomolgus monkeys and humans were relatively low ¤Table 1¥. In humans, the intestinal CL int value of paroxetine was 0.059 mL/min/mg protein, and those of the other compounds were lower than 0.018 mL/min/mg protein. Paine et al. reported that CYP2D6 protein was expressed in human intestine. 7¥ In the same way as for the intestinal value, paroxetine showed the highest hepatic CL int value among human CYP2D6 substrates: CL int © 2.0 mL/min/mg protein ¤Table 1¥. Therefore, the metabolic activity toward paroxetine in human intestine might be due to CYP2D6. As a result, the metabolic activity of CYP2D6 in human intestine might be higher than that of CYP2D in cynomolgus monkey intestine, although the details are unclear.
In conclusion, there is a possibility that the greatly higher metabolic activity of CYP2C and CYP4F in cynomolgus monkey intestine is one of the causes of species differences of intestinal first-pass metabolism between cynomolgus monkeys and humans. Fig. 4 . Effects of 17-ODYA on metabolism of astemizole (A) and terfenadine (B) in cynomolgus monkey intestinal microsomes 17-ODYA, an inhibitor of the CYP4 family, was preincubated with cynomolgus monkey intestinal microsomes and NADPH at 37°C for 30 min in the absence of astemizole and terfenadine; the mixture was then incubated with 200 nM test compound at 37°C for 15 min. Each symbol is expressed as percentage of substrate consumed and represents the mean ± S.D. of three determinations.

